Endpoints News 生物医药· Ayisha Sharma·· 26 天前AI 评分46
Roche KRAS G12C 抑制剂头对头试验显示降低既往治疗 NSCLC 死亡风险 44%
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
AI 导读
Roche 的新一代 KRAS G12C 抑制剂在既往接受过治疗的突变非小细胞肺癌头对头试验中,使死亡风险降低 44%。
正文
MADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news